SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, announces that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets.
Read the full article: SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion //
Source: https://www.businesswire.com/news/home/20251215899012/en/SK-Capital-Announces-Definitive-Agreement-to-Invest-in-Swixx-BioPharma-AG-to-Drive-the-Next-Phase-of-Growth-and-Global-Expansion